Cargando…
Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical presentation can range from mild symptoms such as acute confusion to non-convulsive seizures, severe irreversible coma, and death. The benefit of methylene blue use in treating ifosfamide-induced metabol...
Autores principales: | Vakiti, Anusha, Pilla, Ravi, Alhaj Moustafa, Muhamad, Joseph, Jacinth J., Shenoy, Aarthi G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069036/ https://www.ncbi.nlm.nih.gov/pubmed/30083561 http://dx.doi.org/10.1177/2324709618786769 |
Ejemplares similares
-
Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature
por: Furui, Yu, et al.
Publicado: (2023) -
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
por: Pelgrims, J, et al.
Publicado: (2000) -
Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue
por: Snyder, Matthew, et al.
Publicado: (2017) -
Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report
por: Hamilton, Juliette E., et al.
Publicado: (2020) -
A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature
por: Chain, Gabriel, et al.
Publicado: (2022)